Age-Related Macular Degeneration (AMD)
Advanced Cell Technology (ACT), an early leader in the field of regenerative medicine, recently published data in The Lancet that shows positive results from its ongoing stem cell transplantation trial. The clinical trial uses…Read More
Babies born with Retinopathy of prematurity (ROP), one of the most common causes of vision loss in children, stand to benefit from an exciting discovery made possible, in part, by Fighting Blindness Canada. The…Read More
An additional treatment option for people with wet age-related macular degeneration (AMD) will soon be available in Canada. Health Canada has just approved Eyelea, a drug made and marketed by Bayer Inc….Read More
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.